Scientia Vascular Appoints Rick Randall to Its Board
October 23, 2018
WEST VALLEY CITY, Utah–(BUSINESS WIRE)–Scientia Vascular, LLC, a commercial-stage medical device company with
patented, proprietary, and FDA-approved vascular access technology,
recently appointed Rick Randall as executive director to its board. Rick
has served as CEO for both private and publicly traded companies such as
Target Therapeutics, Innovasive Devices, TranS1 and OMNIlife Science.
Mr. Randall brings extensive experience in medical device general
management, strategic planning, product/procedure marketing and
commercialization.
“Rick brought the first interventional neuro company, Target
Therapeutics, public and was key in developing the first neuro
technologies. His joining our team reflects the great potential our
product lines bring to patients and neuro and peripheral
interventionalists worldwide,” said company founder and CEO, John
Lippert.
Sales and Marketing Vice President David Rardin stated, “The tremendous
response we’ve had clinically is accelerating our product adoption, and
Rick’s executive role on our team will help us capture this opportunity.”
“Scientia’s next-generation vascular access technology is perfectly
suited to the stringent demands of the rapidly growing interventional
stroke treatment market,” Rick Randall commented. “I look forward to
joining the Scientia board and management team as they continue to
redefine the way the neuro and peripheral vascular system is accessed
and treated.”
Rick Randall has over 40 years of experience in the medical device
industry, primarily focused on introducing novel, minimally invasive
therapeutic products to global markets.
Scientia Vascular develops its own leading-edge neuro and peripheral
access technologies, which are patented and form the basis for their
proven superior performance.
Contacts
Scientia Vascular, LLC
Stacy Lippert
slippert@scientiavascular.com
(888)
385-9016